Determination of cetirizine dihydrochloride, related impurities and preservatives in oral solution and tablet dosage forms using HPLC
An HPLC method was developed and validated for the determination of cetirizine dihydrochloride (CZ) as well as its related impurities in commercial oral solution and tablet formulations. Furthermore, two preservatives associated with the drug formulations, namely, propyl (PP) and butylparabens (BP)...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2004-10, Vol.36 (2), p.341-350 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | An HPLC method was developed and validated for the determination of cetirizine dihydrochloride (CZ) as well as its related impurities in commercial oral solution and tablet formulations. Furthermore, two preservatives associated with the drug formulations, namely, propyl (PP) and butylparabens (BP) were successfully determined by this method. The chromatographic system used was equipped with a Hypersil BDS C18, 5
μm column (4.6 × 250
mm) and a detector set at 230
nm in conjunction with a mobile phase of 0.05
M dihydrogen phosphate:acetonitrile:methanol:tetrahydrofuran (12:5:2:1, v/v/v/v) at a pH of 5.5 and a flow rate of 1
ml min
−1. The calibration curves were linear within the target concentration ranges studied, namely, 2×10
2–8×10
2
μg ml
−1 and 1–4
μg ml
−1 for CZ, 20–100
μg ml
−1 for preservatives and 1–4
μg ml
−1 for CZ related impurities. The limits of detection (LOD) and quantitation (LOQ) for CZ were, respectively, 0.10 and 0.34
μg ml
−1 and for CZ related impurities were in the ranges of 0.08–0.26
μg ml
−1 and 0.28–0.86
μg ml
−1, respectively. The method proved to be specific, stability indicating, accurate, precise, robust and could be used as an alternative to the European pharmacopoeial method set for CZ and its related impurities. |
---|---|
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/j.jpba.2004.07.002 |